Burden, R.E., Gormley, J.A., Kuehn, D., et al. (2012) Inhibition of Cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas. Biochimie, 94, 487-493. doi:10.1016/j.biochi.2011.08.017

has been cited by the following article:

• TITLE: Antibody research targeting Cathepsin S for cancer therapy

  AUTHORS: Hang Fai Kwok

  KEYWORDS: Cathepsin S; Tumor; Therapeutic Antibody

  JOURNAL NAME: Advances in Bioscience and Biotechnology, Vol.4 No.4A, April 29, 2013

  ABSTRACT: Cathepsin S is a cysteine protease highly expressed in many type of cancers including colorectal, prostate, breast, and glioblastoma’s. It is involved in tumor progression through extracellular matrix remodeling. In recent years, antibody research specifically targeting Cathepsin S to block/inhibit tumorigenic effects were generated some positive preclinical data. This antagonistic antibody was demonstrating efficacy in multiple in vitro/in vivo cancer models both as a monotherapy and in combination with approved agents. This mini-review provides an overview of therapeutic antibody targeting Cathepsin S strategies in the last half decade, focusing on the rationale of cell-surface Cathepsin S targeted and their potential clinical application.